p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression

International Journal of Cancer

Volumn 74, Issue 1, 1997, Pages 26-30

  Piccinin, Sara ^a   Doglioni, Claudio ^b   Maestro, Roberta ^a   Vukosavljevic, Tamara ^a   Gasparotto, Daniela ^a   D'Orazi, Claudia ^b   Boiocchi, Mauro ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Hospital of Belluno   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE; PROTEIN P16;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; MELANOMA; PRIORITY JOURNAL; TUMOR GROWTH;

CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; EXONS; GENES, TUMOR SUPPRESSOR; HUMANS; MELANOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; REFERENCE VALUES; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030917395     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970220)74:1<26::AID-IJC5>3.0.CO;2-2     Document Type: Article

References (22)

1. CAIRNS, P., MAO, L., MERLO, A., LEE, D.J., SCHWAB, D., EBY, Y., TOKINO, K., VAN DER RIET, P., BLAUGRUND, J.E. and SIDRANSKY, D., Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265, 415-416 (1994).
2. CANNON-ALBRIGHT, L.A. and 15 OTHERS, Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-22. Science, 258, 1148-1152 (1992).
3. DEI TOS, A.P., MAESTRO, R., DOGLIONI, C., PICCININ, S., DELLA LIBERA, D., BOIOCCHI, M. and FLETCHER, C.D.M., Tumor suppressor genes and related molecules in leiomyosarcoma. Amer. J. Pathol., 148, 1037-1045 (1996).
4. FOUNTAIN, J.W. and 12 OTHERS, Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. nat. Acad. Sci. (Wash.), 89, 10557-10561 (1992).
5. GLENDENING, J.M., FLORES, J.F., WALKER, G.J., STONE, S., ALBINO, A.P. and FOUNTAIN, J.W., Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res., 55, 5531-5535 (1995).
6. KAMB, A., GRUIS, N.A., WEAVER-FELDHAUS, J., LIU, Q., HARSHMAN, K., TAVTIGIAN, S.V., STOCKERT, E., DAY III, R.S., JOHNSON, B.E. and SKOLNICK, M.H., A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440 (1994a).
7. KAMB, A., LIU, Q., HARSHMAN, K. and TAVTIGIAN, S., Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265, 416-417 (1994b).
8. KAMB, A. and 23 OTHERS, Analysis of the p16 gene (CDKN2 ) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature (Genet.), 8, 22-26 (1994c).
9. NOBORI, T., MIURA, K., WU, D.J., LOIS, A., TAKABAYASHI, K. and CARSON, D.A., Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368, 753-756 (1994).
10. OKAMOTO, A., DEMETRICK, D.J., SPILLARE, E.A., HAGIWARA, K., HUSSAIN, S.P., BENNETT, W.P., FORRESTER, K., GERWIN, B., SERRANO, M., BEACH, D.H. and HARRIS, C.C., Mutations and altered expression of p16INK4 in human cancer. Proc. nat. Acad. Sci. (Wash.), 91, 11045-11049 (1994).
11. OTSUKI, T., CLARK, H.M., WELLMANN, A., JAFFE, E.S. and RAFFELD, M., Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res., 55, 1436-1440 (1995).
12. REED, J.A., LOGANZO, F., SHEA, C.R., WALKER, G.J., FLORES, J.F., GLENDENING, J.M., BOGDANY, J.K., SHIEL, M.J., HALUSKA, F.G., FOUNTAIN, J.W. and ALBINO, A.P., Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res., 55, 2713-2718 (1995).
13. SERRANO, M., HANNON, G.J. and BEACH, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366, 704-707 (1993).
14. SPRUCK III, C., GONZALEZ-ZULUETA, M., SHIBATA, A., SIMONEAU, A.R., LIN, M-F., GONZALES, F., TSAI, Y.C. and JONES, P.A., p16 gene in uncultured tumours. Nature (Lond.), 370, 183-184 (1994).
15. WEAVER-FELDHAUS, J., GRUIS, N.A., NEUHAUSEN, S., LE PASLIER, D., STOCKERT, E., SKOLNICK, M.H. and KAMB, A., Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc. nat. Acad. Sci. (Wash.), 91, 7563-7567 (1994).
16. WÖLFEL, T., HAUER, M., SCHNEIDER, J., SERRANO, M., WÖLFEL, C., KLEHMANN-HIEB, E., DE PLAEN, E., HANKELN, T., MEYER ZUM BÜSCHENFELDE, K-H. and BEACH, D., A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science, 269, 1281-1284 (1995).
17. XIAO, S., LI, D., CORSON, J.M., VIJG, J. and FLETCHER, J.A., Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res., 55, 2968-2971 (1995a).
18. XIAO, S., LI, D., VIJG, J., SUGARBAKER, D.J., CORSON, J.M. and FLETCHER, J.A., Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene, 11, 511-515 (1995b).
19. YANG, R., GOMBART, A.F., SERRANO, M. and KOEFFLER, H.P., Mutational effects on the p16INK4a tumor suppressor protein. Cancer Res., 55, 2503-2506 (1995).
20. YEUNDALL, W.A. and JAKUS, J., Cyclin kinase inhibitors add a new dimension to cell cycle control. Oral. Oncol. Europ. J. Cancer, 31B, 291-298 (1995).
21. ZHANG, S.-Y., KLEIN-SZANTO, A.J.P., SAUTER, E.R., SHAFARENKO, M., MITSUNAGA, S., NOBORI, T., CARSON, D.A., RIDGE, J.A. and GOODROW, T.L., Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res., 54, 5050-5053 (1994).
22. ZUO, L., WEGER, J., YANG, Q., GOLDSTEIN, A.M., TUCKER, M.A., WALKER, G.J., HAYWARD, N. and DRACOPOLI, N.C., Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature (Genet.), 12, 97-99 (1996).